Table 2 Treatment characteristics
Follow-up time, median (months) | 28.3 |
Completeness of follow-up (%) | 91.6 |
Time elapsed since diagnosis and initiation of palbociclib (years) | |
Median (IQR) | 3.9 (0.6–9.5) |
Min–max | 0.0–23.9 |
Previous lines of treatment for locoregional or advanced disease* | |
0 lines, n (%) | 35 (26.7) |
1 line, n (%) | 58 (44.3) |
2 lines, n (%) | 18 (13.7) |
3 lines, n (%) | 13 (9.9) |
4 lines, n (%) | 5 (3.8) |
≥ 5 lines, n (%) | 2 (1.6) |
Concurrent AI | |
Anastrazole, n (%) | 15 (11.5) |
Exemestane, n (%) | 10 (7.6) |
Letrozole, n (%) | 106 (80.9) |
Other treatments received concurrently to palbociclib + AI, n (%) | |
LHRH agonist | 31 (23.7) |
Bisphosphonates or monoclonal antibody anti- RANK/RANKL | 76 (58.0) |
Radiotherapy | 26 (19.9) |
Surgery | 9 (6.9) |
Duration of palbociclib treatment, months, median (IQR) | 17.53 (7.8– 29.1) |
Number of palbociclib cycles, median (IQR) | 16 (7–29) |
Initial dose (mg) of palbociclib, n (%) [Unknown, n = 6] | |
125 mg | 118 (94.4) |
100 mg | 7 (5.6) |
75 mg | 0 (0.0) |
Reduced initial dose of palbociclib, n (%) [Unknown, n = 55] | |
Yes | 40 (52.6) |
No | 36 (47.4) |
Treatment status at cut-off date, n (%) | |
Patients with palbociclib treatment on-going at cut-off date | 40 (30.5) |
Discontinued treatment | 91 (69.5) |
Reasons for treatment discontinuation | |
Disease progression | 67 (73.6) |
Death | 1 (1.1) |
Adverse event | 14 (15.4) |
Patient refusal | 2 (2.2) |
Other cause | 4 (4.4) |
Unknown reason | 3 (3.3) |
Continuation of treatment (n = 91) | |
No systemic treatment after palbociclib | 12 (13.2) |
One or more subsequent systemic treatments | 79 (86.8) |